Press
Releases
Press Releases
AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 20, 2021-- AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene
Oct 20, 2021
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
No adverse events or serious adverse events related to drug product in 14 patients treated in Phase 1 and 2 Fabry disease trials and Phase 1/2 Gaucher disease trial Post-gene therapy administration safety data out 4½ years for first patient dosed AVROBIO leads way with new industry-leading
Oct 19, 2021
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
New safety data to be reported from clinical trials in Fabry disease and Gaucher disease type 1 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today
Oct 06, 2021
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 5, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Oct 05, 2021
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Sep 03, 2021
AVROBIO to Participate at Four Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming
Sep 01, 2021
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
U.S. Food and Drug Administration granted Fast Track Designation to AVR-RD-04 for cystinosis Company is planning to initiate multiple registration trials in 2022 Multiple data and regulatory updates anticipated over next 12 months CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2021-- AVROBIO, Inc .
Aug 05, 2021
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Aug 04, 2021
AVROBIO to Present at Two Upcoming Investor Conferences in August
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming
Aug 02, 2021
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Jul 08, 2021
Displaying 1 - 10 of 28